Journal: Diabetes Technology & Therapeutics

Article Title: Clinical Practice Recommendations on the Routine Use of Eversense, the First Long-Term Implantable Continuous Glucose Monitoring System

doi: 10.1089/dia.2018.0397

Figure Lengend Snippet: Decision tree for glucose monitoring. Selection criteria for the optimal glucose monitoring device. Intensified insulin users have a wide choice of glucose monitoring devices according to their personal preference. With addition of further clinical indications or lifestyle restrictions from top to bottom, the use of specific devices is recommended. isCGM, intermittent scanning continuous glucose monitoring; LTI rtCGM, long-term implantable real-time CGM; SMBG, self-monitoring of capillary blood glucose; TC rtCGM, transcutaneous real-time CGM.

Article Snippet: The first implantable long-term rtCGM (LTI rtCGM) has the tradename Eversense ® (Senseonics, Maryland) and is the only implantable glucose monitoring technology currently available on the market.

Techniques: Selection

Journal: Diabetes, Obesity & Metabolism

Article Title: Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/dom.70008

Figure Lengend Snippet: Forest plots of randomised controlled trials that compared continuous glucose monitoring vs. blood glucose monitoring for (A) HbA1c (%), (B) time in range (%), (C) time below range (<3.9 mmol/L) (%), (D) time below range (<3.0 mmol/L) (%), (E) time above range (>10 mmol/L) (%), (F) time above range (>13.9 mmol/L) (%) and (G) coefficient of variability. *, Wada, 2020 data for 1F is % TAR (>13.3 mmol/L). CGM, continuous glucose monitoring; isCGM, intermittently scanned CGM; rtCGM, real‐time CGM; BGM, blood glucose monitoring; HbA1c, glycated haemoglobin; TAR, time above range.

Article Snippet: Bergenstal USA , T2DM with an HbA1c ≥ 7.0% treated with metformin ± sulphonylurea, metformin ± incretin or insulin ± metformin , 114 , 31 (53%) [rtCGM arm] 32 (58%) [control arm] , rtCGM (Dexcom SevenPlus) vs. BGM (≥4 times daily with structured review) , HbA1c , 16 weeks , rtCGM: 8.19% BGM: 7.85% , HbA1c: no difference between groups; −1.12% vs. −0.82%; p = 0.11 TBR: lower in rtCGM group vs. BGM group.

Techniques:

Journal: Diabetes, Obesity & Metabolism

Article Title: Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real‐world study

doi: 10.1111/dom.70369

Figure Lengend Snippet: Bland–Altman analysis for all phases: (A) overall, (B) in‐lab and (C) home for the three rtCGM systems compared to reference measurements. BG, blood glucose; CGM, continuous glucose monitoring.

Article Snippet: Three rtCGM systems were used in parallel (Dexcom G7 [Dexcom], FreeStyle Libre 3 [Abbott], and the Simplera [Medtronic]) and were tested against reference capillary blood glucose (Contour Next One, Ascensia Diabetes Care) levels in adult individuals with T1D.

Techniques:

Journal: Diabetes, Obesity & Metabolism

Article Title: Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/dom.70008

Figure Lengend Snippet: Forest plots of randomised controlled trials that compared continuous glucose monitoring vs. blood glucose monitoring for (A) HbA1c (%), (B) time in range (%), (C) time below range (<3.9 mmol/L) (%), (D) time below range (<3.0 mmol/L) (%), (E) time above range (>10 mmol/L) (%), (F) time above range (>13.9 mmol/L) (%) and (G) coefficient of variability. *, Wada, 2020 data for 1F is % TAR (>13.3 mmol/L). CGM, continuous glucose monitoring; isCGM, intermittently scanned CGM; rtCGM, real‐time CGM; BGM, blood glucose monitoring; HbA1c, glycated haemoglobin; TAR, time above range.

Article Snippet: Cox and colleagues randomised noninsulin‐using individuals living with T2DM to an intervention using Dexcom G5TM rtCGM plus a GEM programme that incorporated 4 sessions of diabetes education along with one‐week periods of rtCGM‐derived feedback on postprandial changes.

Techniques: